 |
2 Diseases |  |
3 Trials |
|
3 Trials |  |
196 News |  |
| 123» |
- reparixin (DF 1681Y) / Dompe
Distinctive Alterations in the Emperipolesis between Neutrophils and Megakaryocytes from the Bone Marrow of Gata1low Mice Documented By Time-Lapse Observations () - Dec 7, 2024 - Abstract #ASH2024ASH_8604;
The discovery that the MK from these patients express an IL-8 (CXCL1 in the mouse) signature3, a potent chemo-attractant for Neu4, lead us to discovery that treatment of the Gata1low mouse model with Reparixin, an inhibitor of CXCR1/CXCR2 (the CXCL1 receptors), rescues both fibrosis and pathological MK-Neu emperipolesis in their bone marrow5...6.Huang FY et al. Blood Adv 2022; 6 : 2081.
- | SB225002 / GSK, reparixin (DF 1681Y) / Dompe
Preclinical, Journal: Blockade of the Platelet-Driven CXCL7-CXCR1/2 Inflammatory Axis Prevents Murine Cerebral Aneurysm Formation and Rupture. (Pubmed Central) - Nov 5, 2024
Blood Adv 2022; 6 : 2081. Mice treated with 1
- ||||||||| reparixin (DF 1681Y) / Dompe
Trial termination: REPAVID-22: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (clinicaltrials.gov) - Oct 23, 2024
P3, N=409, Terminated, Sponsor: Domp
Mice treated with 1 Recruiting --> Terminated; The study was stopped due to futility as per protocol
- | reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) (clinicaltrials.gov) - Oct 17, 2024
P2, N=26, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Terminated; The study was stopped due to futility as per protocol Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2025
- || reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Oct 4, 2024
P2, N=66, Recruiting, Sponsor: Domp
Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2025 Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Apr 2025 --> Aug 2025
- | Journal: The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-?, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. (Pubmed Central) - Jul 31, 2024
These results suggest that future therapies for myelofibrosis should consider combining JAK1/2 inhibitors with drugs targeting hematopoietic stem cells (p27Kip1) or the pro-inflammatory milieu (TGF-? or CXCL1).
- || reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Jun 10, 2024
P2, N=66, Recruiting, Sponsor: Domp
or CXCL1). Trial completion date: Jun 2024 --> May 2025 | Trial primary completion date: May 2024 --> Apr 2025
- reparixin (DF 1681Y) / Dompe
Treating hyperinflammation as an unmet need in CAP: Investigational agent reparixin and the REPAVID-22 trial (Innovation Hub 3) - Apr 30, 2024 - Abstract #ATS2024ATS_9763;
Douglas as he discusses Interleukin-8 (IL-8) mediated signaling, the role of inflammation with community-acquired pneumonia (CAP), and an overview of the investigational agent reparixin being studied in the ongoing REPAVID-22 clinical trial. He will also review a clinical case of severe CAP with a hyperinflammatory phenotype.
- reparixin (DF 1681Y) / Dompe
Targeting neutrophil injury-pathways and fibrogenesis in non-parenchymal immune tissue-like liver organoids generated from human induced pluripotent stem cells (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1949;
He will also review a clinical case of severe CAP with a hyperinflammatory phenotype. Intercellular pathways were identified using single-cell RNA sequencing and CellCHAT, and modulated via CXCR1/2-blockade
- | reparixin (DF 1681Y) / Dompe
Journal, Cancer stem, PD(L)-1 Biomarker, IO biomarker: Interferon-? induces differentiation of cancer stem cells and immunosuppression in hepatocellular carcinoma by upregulating CXCL8 secretion. (Pubmed Central) - Mar 13, 2024
triggers immunosuppression and cancer stem cell differentiation in hepatocellular carcinoma by upregulating CXCL8 secretion. This discovery provides a novel approach to enhance the effectiveness of HCC treatment in the future.
- | reparixin (DF 1681Y) / Dompe
Journal: Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. (Pubmed Central) - Mar 9, 2024
Overall, we demonstrated that TAMs boosted PDAC cell glycolysis through the IL-8/STAT3/GLUT3 signaling pathway. Our cumulative findings suggest that the abrogation of TAM-induced tumor glycolysis by reparixin might exhibit an antitumor impact and offer a potential therapeutic target for PDAC.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, reparixin (DF 1681Y) / Dompe
Journal: The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. (Pubmed Central) - Feb 27, 2024
Our cumulative findings suggest that the abrogation of TAM-induced tumor glycolysis by reparixin might exhibit an antitumor impact and offer a potential therapeutic target for PDAC. Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.
- | reparixin (DF 1681Y) / Dompe
Journal: Blocking CXCR1/2 attenuates experimental periodontitis by suppressing neutrophils recruitment. (Pubmed Central) - Feb 8, 2024
Suppressing the recruitment of neutrophils to inflamed sites with the CXCR1/2 inhibitor reparixin reduced alveolar bone loss in PD mice. In this study, we not only revealed that neutrophils exhibit a heterogeneously stronger pro-inflammatory capacity in the inflamed alveolar bone of PD patients but also provided a precise therapeutic treatment for PD involving the suppression of neutrophil recruitment.
- | reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) (clinicaltrials.gov) - Jan 1, 2024
P2, N=26, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- || tigatuzumab (CS-1008) / Daiichi Sankyo, reparixin (DF 1681Y) / Dompe
Review, Journal: Neutrophils as potential therapeutic targets for breast cancer. (Pubmed Central) - Dec 5, 2023
P2
This review summarizes the evidence regarding the close relationship between neutrophils and BC, emphasizing the critical roles of neutrophils in regulating metabolic and immune pathways. Additionally, we summarize the existing therapeutic approaches that target neutrophils, highlighting the challenges, and affirming the rationale for continuing to explore neutrophils as a viable therapeutic target in BC management.
- | reparixin (DF 1681Y) / Dompe
Journal: Plasmon-enhanced circular dichroism spectroscopy of chiral drug solutions. (Pubmed Central) - Oct 22, 2023
Considering realistic dilute solutions of reparixin dissolved in water with concentration ?5 mg/ml and nl volume, we find a circular-dichroism differential absorption enhancement factor of the order ?20 and chirality-induced polarization distortion upon surface plasmon polariton excitation. Our results are relevant for the development of innovative chiroptical sensors capable of measuring the enantiomeric imbalance of chiral drug solutions with nl volume.
- |||| reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: REPAVID-22: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (clinicaltrials.gov) - Oct 5, 2023
P3, N=526, Recruiting, Sponsor: Domp
Our results are relevant for the development of innovative chiroptical sensors capable of measuring the enantiomeric imbalance of chiral drug solutions with nl volume. Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- || reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Oct 5, 2023
P2, N=66, Recruiting, Sponsor: Domp
Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Oct 2023 --> May 2024
- || reparixin (DF 1681Y) / Dompe
Enrollment open: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) (clinicaltrials.gov) - Oct 3, 2023
P2, N=26, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Oct 2023 --> May 2024 Not yet recruiting --> Recruiting
- || Review, Journal: Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain. (Pubmed Central) - Aug 16, 2023
Recent research has shown that multitarget antagonists of chemokine receptors, such as CCR2/5 (cenicriviroc), CXCR1/2 (reparixin), and CCR2/CCR5/CCR8 (RAP-103), are also very effective painkillers...However, members of the chemokine family are still underestimated pharmacological targets for pain treatment. In this article, we review the literature and provide new insights into the role of chemokines and their receptors in neuropathic pain.
- | reparixin (DF 1681Y) / Dompe
Journal: CXCR2 Is Deregulated in ALS Spinal Cord and Its Activation Triggers Apoptosis in Motor Neuron-Like Cells Overexpressing hSOD1-G93A. (Pubmed Central) - Aug 2, 2023
toxicity, significantly inhibiting the chemokine-induced cell death. Altogether, data further support a role of CXCR2 axis in ALS etiopathogenesis and confirm its pharmacological modulation as a candidate therapeutic strategy.
- Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, reparixin (DF 1681Y) / Dompe
Timing of anti-thymocyte globulin infusion affects islet engraftment after intraportal allotransplantation in patients with T1DM (Indigo A) - Jul 7, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_319;
Tacrolimus and myfortic were initiated at the time of ATG infusion. Additional basiliximab was given for induction in
- || reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Jun 8, 2023
P2, N=66, Recruiting, Sponsor: Domp
Additional basiliximab was given for induction in Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Oct 2023
- || reparixin (DF 1681Y) / Dompe
Retrospective data, Review, Journal: Reparixin improves survival in critically ill and transplant patients: A meta-analysis. (Pubmed Central) - May 10, 2023
Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Oct 2023 The findings of this meta-analysis indicate that reparixin, an anti-inflammatory drug, improved survival in critically ill or transplant patients (including both COVID-19 and non-COVID-19 patients) without increasing the risk of infection.
- | cytarabine / Generic mfg.
Journal, IO biomarker: The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leukemia (Pubmed Central) - Apr 29, 2023
Reparixin combined with Ara-C can synergistically inhibit the malignant biological behaviors of U937 cells such as proliferation, invasion, migration and clone formation, and induce autophagy and apoptosis. The mechanism may be related to affecting the proteins expression of Bcl-2 family and down-regulating the proteins expression of CXCR family, while inhibiting the PI3K/AKT/NF-?B signaling pathway.
- || reparixin (DF 1681Y) / Dompe
New P2 trial: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) (clinicaltrials.gov) - Apr 28, 2023
P2, N=26, Not yet recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- reparixin (DF 1681Y) / Dompe
CXCL6 Upregulates COL1A1 and COL1A2 mRNAs in IPF Fibroblasts by a Post-transcriptional Mechanism (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_5568;
CXCL6 family signaling in fibroblasts may drive fibrotic pathology independently of TGF? by stabilizing COL1A1 and COL1A2 mRNAs.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, reparixin (DF 1681Y) / Dompe
The role of CXCL1 in crosstalk between breast cancer cells with ESR1 mutations and lymphatic endothelial cells (Section 16; Poster Board #8) - Mar 14, 2023 - Abstract #AACR2023AACR_6113;
These findings implicate CXCL1-CXCR1/2 signaling as a critical event in the growth of breast cancer with ESR1 mutation and metastasis. Therefore, we have provided evidence that supports the hypothesis that functional inhibition of the CXCL1 and CDK4/6 signaling pathway has the potential to circumvent endocrine resistant tumor growth and metastasis.
- | reparixin (DF 1681Y) / Dompe
Journal: Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1 model of myelofibrosis. (Pubmed Central) - Mar 3, 2023
content and marrow fibrosis, these results identify neutrophil/megakaryocyte emperipolesis as the cellular interaction that links interleukin-8 to TGF-? abnormalities in the pathobiology of marrow fibrosis.
- ||| reparixin (DF 1681Y) / Dompe
Enrollment open: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Feb 28, 2023
P2, N=66, Recruiting, Sponsor: Domp
abnormalities in the pathobiology of marrow fibrosis. Not yet recruiting --> Recruiting
- | Jakafi (ruxolitinib) / Novartis, Incyte, reparixin (DF 1681Y) / Dompe
Journal: Prevention of Chemotherapy-Induced Peripheral Neuropathy by Inhibiting C-X-C Motif Chemokine Receptor 2. (Pubmed Central) - Feb 12, 2023
Reparixin and ruxolitinib blocked oxaliplatin-induced allodynia but not vincristine-induced allodynia, which suggests that CXCR2-related pathways are associated with the development of oxaliplatin-induced neuropathy. Together with the above results, this suggests that the prevention of oxaliplatin-induced neuropathy by CXCR2 inhibition can lead to successful chemotherapy, and it is important to provide appropriate countermeasures against CIPN development for each specific chemotherapeutic agent.
- reparixin (DF 1681Y) / Dompe, ladarixin (DF-2156A) / Dompe
Allosteric inhibition of CXCR1/2 by an orally bioavailable chemokine receptor inhibitor attenuates allergic lung inflammation in mice (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1531;
These observations indicate that allosteric inhibition of CXCR1/2 by an orally bioavailable chemokine receptor-inhibitor is sufficient to attenuate Th2/Th17-associated allergic lung inflammation. Oral ladarixin maybe an effective therapeutic strategy in asthma.
- | reparixin (DF 1681Y) / Dompe
Enrollment change, Trial withdrawal, Metastases: To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer (clinicaltrials.gov) - Jan 23, 2023
P2, N=0, Withdrawn, Sponsor: Domp
Oral ladarixin maybe an effective therapeutic strategy in asthma. N=76 --> 0 | Recruiting --> Withdrawn
- || Kineret (anakinra) / SOBI, reparixin (DF 1681Y) / Dompe
yes #reparixin (tablets) at home (but not available and not EBM) #anakinra (sc or iv) at H arrival (but not common practice and not EBM) + full LMWH #corticosteroids (possibly short course) when lot of oxygen is required who will be so brave to test this in a large RCT? (Twitter) - Dec 5, 2022
- ||||| reparixin (DF 1681Y) / Dompe
Clinical: Today for the first time I was a speaker at a medical congress. The topic was: #reparixin in critically ill and transplant patients🤕🩺 Hot topic and interesting results! ‼️Wait for them‼️ @giovannilandoni @SRAnesthesiaICU #AreaCritica22 #ICU (Twitter) - Dec 2, 2022
- || reparixin (DF 1681Y) / Dompe
P2 data, Journal: Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia". (Pubmed Central) - Nov 24, 2022
N=76 --> 0 | Recruiting --> Withdrawn No abstract available
- || reparixin (DF 1681Y) / Dompe
P2 data, Journal: Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. (Pubmed Central) - Nov 23, 2022
No abstract available No abstract available
- |||| reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: REPAVID-22: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (clinicaltrials.gov) - Oct 13, 2022
P3, N=526, Recruiting, Sponsor: Domp
No abstract available Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Sep 2023
- | reparixin (DF 1681Y) / Dompe
Retrospective data, Journal: The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials. (Pubmed Central) - Aug 22, 2022
Our meta-analysis of randomized trials suggests that short-term inhibition of CXCL8 activity improved survival in patients at high risk for in-hospital mortality without increasing the risk of infection. PROSPERO, identifier CRD42021254467.
- |||| reparixin (DF 1681Y) / Dompe
New P2 trial: Add-on Reparixin in Adult Patients With ARDS (clinicaltrials.gov) - Aug 11, 2022
P2, N=73, Not yet recruiting, Sponsor: Domp
- |||| reparixin (DF 1681Y) / Dompe
Trial completion date, Trial primary completion date: REPAVID-22: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (clinicaltrials.gov) - Aug 4, 2022
P3, N=474, Recruiting, Sponsor: Domp
PROSPERO, identifier CRD42021254467. Trial completion date: Jul 2022 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||| reparixin (DF 1681Y) / Dompe
Retrospective data: My first article is published! It’s a meta-analysis of #RCT to evaluate the effect of #reparixin on survival of critically ill patients As a 2Y Med student, I’m so excited and thankful to my mentors @giovannilandoni @PiemontiL @tscquizzato @azangrillo 🔗 https://t.co/1XEuX3bSp0 https://t.co/AvMCONoTcp (Twitter) - Jul 26, 2022
- ||| reparixin (DF 1681Y) / Dompe
Clinical: There are treatments for the various other high cytokine values seen in the test panel. eg. "reparixin, a clinically available, oral IL-8 receptor (CXCR-1/-2) blocker" https://t.co/ti0yG7ikUX (Twitter) - Jul 26, 2022
- |||| reparixin (DF 1681Y) / Dompe
Clinical: A nice press release on #reparixin #RCT (published phase 2) #COVID19 #SARSCoV2 This drug was first administered to #covid19 pts in spring 2020 thanks to @PiemontiL Spoiler: -phase 3 RCT has already been completed -further phase 3 RCT has started https://t.co/quDwUWypwF (Twitter) - Jul 22, 2022
- | reparixin (DF 1681Y) / Dompe
Journal: A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist. (Pubmed Central) - Jul 17, 2022
Further combination of the vaccine with a chemokine inhibitor, reparixin, significantly increased the infiltration of CD4+ and CD8+ T cells into the tumor environment, while the antitumor effect was significantly enhanced. The whole-tumor-cell vaccine Aza-BFcell-106 induced immune-activating responses in both in vitro and in vivo experiments, indicating that this vaccine has great potential to treat advanced malignant tumors.
- reparixin (DF 1681Y) / Dompe
A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia (TP-20 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2649;
P3
This trial did not meet the primary efficacy endpoint due to the low mortality in both arms, yet reparixin showed a promising trend towards limiting disease progression. A confirmatory Phase 3 study is currently underway.
- || reparixin (DF 1681Y) / Dompe
P2 data, Journal: A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. (Pubmed Central) - May 29, 2022
P2/3
In patients with severe COVID-19, reparixin led to an improvement in clinical outcomes when compared with the SOC. A larger phase 3 clinical study is needed to confirm these results.
- |||| reparixin (DF 1681Y) / Dompe
Clinical: Landoni G & Piemonti L et al. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. Infect Dis Ther (2022). Fantastic collaboration with @giovannilandoni https://t.co/RK0hPigChV (Twitter) - May 27, 2022
- | reparixin (DF 1681Y) / Dompe
Journal: The protective effects of reparixin against endothelial ischemia-reperfusion injury. (Pubmed Central) - May 24, 2022
Pretreatment and treatment of endothelial cells with reparixin, which is a CXCL-8 receptor inhibitor, demonstrated a protective effect on cell viability after simulated ischemia-reperfusion. However, further studies to investigate the underlying mechanisms are needed.
- reparixin (DF 1681Y) / Dompe
Trial In Progress: A Phase 2 study to assess the efficacy and safety of reparixin in Breast Cancer related fatigue (Exhibition hall E-Poster Stage 1, Metropolitan Centre, CC) - May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_452;
The planned total enrollment is 76 patients, with evaluation of at least 68 of those enrolled to provide 80% power to detect a =5 point difference in the FACIT-Fatigue score after 16 weeks of treatment. Conclusions This study is currently ongoing to evaluate the efficacy and safety of reparixin to lessen CRF.